Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of BL-001 in Healthy Volunteers
NCT05818306Phase 1Completed
- Sponsor
- Bloom Science
- Start
- Feb 2023
- Primary completion
- May 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BL-001 in Dravet syndrome, amyotrophic lateral sclerosis (ALS) and obesity (4 cohorts), sponsored by Bloom Science. Primary endpoint: Safety and tolerability of BL-001 at Day 28. Started Feb 2023; status: completed.
02
Drugs
BL-001
03
Conditions
Dravet syndromeamyotrophic lateral sclerosis (ALS)obesity
Beyond the preview
Go deeper on NCT05818306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05818306.